COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01565915
Recruitment Status : Unknown
Verified August 2013 by Medicis Global Service Corporation.
Recruitment status was:  Active, not recruiting
First Posted : March 29, 2012
Last Update Posted : August 21, 2013
Sponsor:
Information provided by (Responsible Party):
Medicis Global Service Corporation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine if Perlane-L is safe in increasing cheek volume.

Condition or disease Intervention/treatment Phase
Facial Volume Device: Perlane-L Other: Non-treatment Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 221 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : March 2012
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : December 2013
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Perlane-L
Perlane-L treatment
 Device: Perlane-L
Perlane-L Injection in the midface
Sham Comparator: Non-Treatment
Non-Treatment Arm
 Other: Non-treatment
Non-treatment Arm


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Facial fullness using midface scale [ Time Frame: Week 8 ]
    Change in facial fullness using midface scale.


Secondary Outcome Measures :
  1. Facial fullness using the midface scale [ Time Frame: Up to 12-months post treatment ]
    Change in facial fullness using midface scale.

  2. Subject satisfaction using the GAIS [ Time Frame: Up to 12-months post treatment ]
    Compare treatment satisfaction as compared to no treatment, on the Global Aesthetic Improvement Scale (GAIS)

  3. Aesthetic improvement [ Time Frame: Up to 12-months post treatment ]
    A subjective assessment of aesthetic improvement post baseline


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Loss of Fullness in Midface Area
  • Other items as identified in the protocol

Exclusion Criteria:

  • History of allergy or hypersensitivity to injectable hyaluronic acid gel or lidocaine.
  • Other items as identified in the protocol
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01565915


Locations
Layout table for location information
United States, California
Beverly Hills, California, United States
San Francisco, California, United States
Vista, California, United States
United States, Florida
Aventura, Florida, United States
Coral Gables, Florida, United States
United States, Illinois
Chicago, Illinois, United States
United States, Maryland
Hunt Valley, Maryland, United States
United States, Massachusetts
Chestnut Hill, Massachusetts, United States
United States, New York
Mount Kisco, New York, United States
New York, New York, United States
United States, Oregon
Eugene, Oregon, United States
Sponsors and Collaborators
Medicis Global Service Corporation
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Medicis Global Service Corporation
ClinicalTrials.gov Identifier: NCT01565915    
Other Study ID Numbers: MA-1400-05
First Posted: March 29, 2012    Key Record Dates
Last Update Posted: August 21, 2013
Last Verified: August 2013